The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

被引：107
|
作者：
Rice, GPA
Paszner, B
Oger, J
Lesaux, J
Paty, D
Ebers, G
机构：
[1] London MS Clin, London, ON N6A 5A5, Canada
[2] Univ British Columbia, MS Clin, Vancouver, BC V5Z 1M9, Canada
来源：
NEUROLOGY | 1999年 / 52卷 / 06期
关键词：
D O I：
10.1212/WNL.52.6.1277
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon beta-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
引用
收藏
页码：1277 / 1279
页数：3
相关论文
共 50 条
  • [21] Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients
    Jensen, P. E. H.
    Sellebjerg, F.
    Sondergaard, H. B.
    Sorensen, P. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (10) : 1311 - 1317
  • [22] Antibodies to interferon beta 1b: Longitudinal studies of binding and neutralizing antibodies
    Oger, J
    Paszner, B
    Vincent, A
    Paty, DW
    NEUROLOGY, 1999, 52 (06) : A498 - A499
  • [23] Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
    Fernandez, Oscar
    Agueera, Javier
    Izquierdo, Guillermo
    Millan-Pascual, Javier
    Ramio i Torrenta, Lluis
    Oliva, Pedro
    Argente, Javier
    Berdei, Yasmina
    Maria Soler, Jose
    Carmona, Olga
    Maria Errea, Jose
    Farres, Jordi
    PLOS ONE, 2012, 7 (05):
  • [24] Immunomodulatory effects of interferon-β-1b in patients with multiple sclerosis
    Ossege, LM
    Sindern, E
    Patzold, T
    Malin, JP
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (06) : 1085 - 1100
  • [25] Treatment of patients with secondary progressive multiple sclerosis with interferon β-1b
    Robert P. Lisak
    Current Neurology and Neuroscience Reports, 2001, 1 (3) : 246 - 248
  • [26] Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis
    Río, J
    Tintoré, M
    Téllez, N
    Nos, C
    Galán, I
    Montalbán, X
    MEDICINA CLINICA, 2005, 124 (04): : 140 - 141
  • [27] Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b:: a randomized trial in multiple sclerosis
    Pozzilli, C
    Antonini, G
    Bagnato, F
    Mainero, C
    Tomassini, V
    Onesti, E
    Fantozzi, R
    Galgani, S
    Pasqualetti, P
    Millefiorini, E
    Spadaro, M
    Dahlke, F
    Gasperini, C
    JOURNAL OF NEUROLOGY, 2002, 249 (01) : 50 - 56
  • [28] Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis
    Carlo Pozzilli
    Giovanni Antonini
    Francesca Bagnato
    Caterina Mainero
    Valentina Tomassini
    Emanuela Onesti
    Roberta Fantozzi
    Simona Galgani
    Patrizio Pasqualetti
    Enrico Millefiorini
    Maria Spadaro
    Frank Dahlke
    Claudio Gasperini
    Journal of Neurology, 2002, 249 : 50 - 56
  • [29] Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
    Hans-Peter Hartung
    Bernd Kieseier
    Douglas S Goodin
    Barry GW Arnason
    Giancarlo Comi
    Stuart Cook
    Massimo Filippi
    Douglas R Jeffery
    Ludwig Kappos
    Timon Bogumil
    Brigitte Stemper
    Rupert Sandbrink
    Yukiko Nakada
    Haruhiko Nakajima
    Susanne Schwenke
    Stephan Lehr
    Jürgen Heubach
    Christoph Pohl
    Joachim Reischl
    Journal of Neuroinflammation, 9
  • [30] Clinical significance of neutralizing antibodies to interferon beta in patients with Multiple Sclerosis
    Zarkesh-Esfahani, Sayyed Hamid
    Zare, Nasrin
    Gharagozloo, Marjan
    Shaygannejad, Vahid
    JOURNAL OF IMMUNOLOGY, 2016, 196
12345